

## 2025 Annual General Meeting

# Board of Director Candidates

### **William (Bill) Carl Fairey Jr. (Current Board Member)**

William (Bill) Carl Fairey Jr. has served as a member of the Ascendis Pharma Board of Directors since September 2022. Mr. Fairey also serves as Chairman of the Board of Directors at Respira Therapeutics and as a member of the Board of Directors at KalVista Pharmaceuticals, Rein Therapeutics (formerly Aileron), and Mirum Pharmaceuticals. A global biopharmaceutical executive with broad P&L, commercial, and medical expertise, Mr. Fairey was previously Executive Vice President and Chief Commercial Officer of MyoKardia (2019–2020), when the company was acquired by Bristol-Myers Squibb. From 2018–2019, he served as Executive Vice President and Chief Operating Officer of ChemoCentryx and from 2001–2017 held positions of increasing responsibility at Actelion Pharmaceuticals, including President of Actelion’s U.S. division; Managing Director and Vice President, Australia Asia Pacific Region; President of Actelion Canada; and Vice President, US Sales & Managed Markets. Mr. Fairey began his pharmaceutical career with the Parke-Davis Division of Warner-Lambert (1988–2000). Mr. Fairey holds a Bachelor of Science degree in Biology from the University of Oregon and an M.B.A. from Saint Mary’s College of California.

### **Albert Cha, M.D., Ph.D. (Current Board Member)**

Albert Cha, M.D., Ph.D. has served as a member of the Ascendis Pharma Board of Directors since November 2014 and has served as its Chairman since May 2021. A Managing Partner with Frazier Life Sciences since 2021, Dr. Cha was previously a Managing Partner at Vivo Capital, where he served in various positions from 2000–2020. Dr. Cha has also served as a member of the Board of Directors of KalVista Pharmaceuticals, Aclaris Therapeutics, Sierra Oncology, Biohaven Pharmaceutical Holding Company, Menlo Therapeutics, and many other public and private biopharmaceutical companies. Mr. Cha is a co-founder of the annual Dermatology Summit and Dermatology Innovation Forum. Early in his career, he worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. Dr. Cha holds Bachelor of Science and Master of Science degrees in Electrical Engineering from Stanford University, as well as M.D. and Ph.D. degrees in Neuroscience from the University of California Los Angeles, where he completed the Medical Scientist Training Program.

### **Lisa Bright (Current Board Member)**

Lisa Bright has served as a member of our board of directors since April 2017. Ms. Bright has over 30 years of executive experience in global life sciences companies and over five years' experience serving as a member of the board of directors of a number of public and private companies. Ms. Bright is currently on the board of Immedica Pharma AB, a pharmaceutical company, and serves as Chair of the board of Metadeq Inc, a medical diagnostics company and DRI Capital, a private equity fund. She previously served as the Chair of the board of Resolution Therapeutics Ltd, a biotechnology company, and as a Non-Executive Director of Dechra Pharmaceuticals PLC, a veterinary pharmaceutical company. She is also an Executive Partner to Syncona Limited, an investment trust dedicated to life science investments. Previously, she served as President International for Intercept Pharmaceuticals, Inc., a biopharmaceutical company, from July 2016 to January 2021, and from November 2014 to July 2016 as Chief Commercial and Corporate Affairs Officer and Senior Vice President, Head of EUCA. During her tenure at Intercept, Ms. Bright oversaw the development of the global launch of an orphan medicine in the United States and Europe, including building the commercial organization in the United States and establishing legal affiliates and teams across Europe and Canada. From 2008 to November 2014, Ms. Bright held various leadership positions at Gilead Sciences Ltd., a biopharmaceutical company, including Vice President, Head of Government Affairs, Europe, Asia, Middle East and Australasia, Vice President and Head of HCV Launch Planning, Vice President and Head of Northern Europe and General Manager, UK and Ireland. Prior to Gilead Sciences, Ms. Bright served in various positions of increasing responsibility at GlaxoSmithKline plc from 1997 to 2006 including Vice President Commercial Planning and Operations and Vice President General Manager NZ and Vice President Head of Sales, UK and Ireland. Prior to that, Ms. Bright also worked at Sanofi from 1992 to 1996 and GlaxoSmithKline from 1989 to 1992. Ms. Bright received her B.Sc. in Pharmacology from University College London, United Kingdom.

### **Lars Holtug M.Sc. (Current Board Member)**

Lars Holtug, M.Sc. has served as a member of the Ascendis Pharma Board of Directors since November 2018. Director of LH2022 since 2015, Mr. Holtug is also Chairman of the Board of Directors at Erhvervsinvest Management, Caretag, and Gaming Investment and its seven subsidiaries. He serves as a board member, Audit Committee Chair, and Remuneration Committee member at Evaxion Biotech. During his career at PriceWaterhouseCoopers Statsautoriseret Revisionspartnerselskab ("PwC") from 1980–2015, Mr. Holtug served as Partner (1993-2015) and as Chairman of PwC in Denmark (2005 –2009). From 2004–2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company Law Association (Dansk Forening for Selskabsret). From 1998–2002, he was a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriserede Revisorer) and, from 1993–1998, was a member of the Auditing Standards Board. Mr. Holtug holds Master of Science and M.B.A.

degrees from Copenhagen Business School and is educated as a state-authorized public accountant in Denmark.

### **Siham Imani (Current Board Member)**

Siham Imani has served as a member of the Ascendis Pharma Board of Directors since September 2022. Currently Ms. Imani is Executive Vice President at Chiesi Group, where she oversees Strategy, Sustainability & Growth (Business Development, Digital Health and Center for Open Innovation) functions. Ms. Imani is also a member of the Board of Directors of the pharmaceutical manufacturing company Laprophan. Before joining Chiesi, Ms. Imani held positions of increasing responsibility at Servier, most recently as Executive Vice President, Corporate Strategy & Business Development (2022–2024), roles in which she contributed to the Group transformation as a leader in Cardio Metabolism and Precision Oncology. From 2011–2017, Ms. Imani held several executive roles at the French pharmaceutical company Ipsen, including Vice President, European Business Unit Pediatric Endocrinology; Vice President Commercial Transformation & Support; Vice President Corporate Strategic Planning; and Executive Committee Secretary. From 2005–2011, Ms. Imani worked for Pierre Fabre and Biosense Webster, part of the Johnson & Johnson Family of Companies in various sales, marketing and management positions and for Pierre Fabre as strategic projects director. Prior to that, she was a management consultant at Arthur D. Little in Paris and Palo Alto and R&D program manager at Orange Labs in San Francisco. Ms. Imani holds an engineering degree with double major in Economics and Chemistry from École Polytechnique in Saclay, France and an M.B.A. from Stanford University.

### **Jan Møller Mikkelsen (Current Board Member)**

Jan Møller Mikkelsen founded Ascendis Pharma and has served as its President and Chief Executive Officer and member of its Board of Directors since December 2007. Mr. Mikkelsen is also a member of the board of VISEN Pharmaceuticals, is Chairman of the Board of Directors at Hummingbird Bioscience, and serves on the advisory board of Inspirion Delivery Technologies. From 2002- 2006, Mr. Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma (now Veloxis Pharmaceuticals), a publicly traded biotechnology company. Previously, Mr. Mikkelsen was President of Maxygen's Protein Pharmaceutical Division (2000-2002), following Maxygen's acquisition of ProFound Pharma, a biopharmaceutical company co-founded by Mr. Mikkelsen where he served as Co-Chief Executive Officer from 1999-2000. Earlier in his career, Mr. Mikkelsen held various positions at Novo Nordisk (1988-1999), including Vice President of Protein Discovery. Mr. Mikkelsen holds a Cand. Scient. degree in Biochemistry from the University of Odense in Denmark and pursued his post-doctoral research in biochemistry at Children's Hospital Oakland in California.